Marie Kosco-Vilbois
Plus aucun poste en cours
Profil
Marie Kosco-Vilbois served as the Chief Scientific Officer at AC Immune SA from 2019 to 2024.
Prior to that, she was the Chief Scientific Officer at NovImmune SA from 2005 to 2019.
She also held positions at Serono Pharmaceutical Research Institute and Glaxo-Welcomes' Research Institute.
Before her career in industry, she was a Scientific Member at Basel Institute for Immunology.
Kosco-Vilbois received her undergraduate degree from Rutgers State University of New Jersey and her doctorate from Medical College of Virginia in 1985.
Anciens postes connus de Marie Kosco-Vilbois
| Sociétés | Poste | Fin |
|---|---|---|
| AC IMMUNE SA | Chief Tech/Sci/R&D Officer | 01/01/2024 |
| NOVIMMUNE SA | Chief Tech/Sci/R&D Officer | 09/01/2019 |
| Serono Pharmaceutical Research Institute | Corporate Officer/Principal | 01/01/2001 |
| Basel Institute for Immunology | Corporate Officer/Principal | - |
| Glaxo-Welcomes' Research Institute | Corporate Officer/Principal | - |
Formation de Marie Kosco-Vilbois
| Rutgers State University of New Jersey | Undergraduate Degree |
| Medical College of Virginia | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Entreprise privées | 3 |
|---|---|
Novimmune SA
 Novimmune SA Medical/Nursing ServicesHealth Services Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland. | Health Services |
| Serono Pharmaceutical Research Institute | |
| Glaxo-Welcomes' Research Institute |
